calcium, magnesium, potassium, and sodium oxybates

**Calcium, magnesium, potassium, and sodium oxybates** is a low-sodium, fixed-dose oral oxybate product marketed as **Xywav**. It contains four oxybate salts that deliver the active moiety oxybate, also known as gamma-hydroxybutyrate. Developed by Jazz Pharmaceuticals, it is a central nervous system depressant indicated in the United States for cataplexy or excessive daytime sleepiness in patients aged 7 years and older with narcolepsy, and for idiopathic hypersomnia in adults. It is supplied as a 0.5 g/mL oral solution, is a Schedule III controlled substance, and is dispensed through the XYWAV and XYREM REMS because of risks including CNS and respiratory depression, misuse, abuse, and diversion. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212690s011lbl.pdf))

Brand names

Xywav

Other names

calcium oxybate + magnesium oxybate + potassium oxybate + sodium oxybatecalcium, magnesium, potassium, and sodium oxybatesmagnesium oxybate + calcium oxybate + potassium oxybate + sodium oxybate